Insider Buying: Fractyl Health (NASDAQ:GUTS) Director Buys 68,493 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director William Bradley acquired 68,493 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was purchased at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the purchase, the director owned 84,622 shares of the company’s stock, valued at $61,774.06. This represents a 424.66% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Fractyl Health Stock Down 1.1%

NASDAQ GUTS traded down $0.01 during midday trading on Thursday, hitting $0.72. 605,424 shares of the company traded hands, compared to its average volume of 3,974,397. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The company has a market cap of $114.85 million, a PE ratio of -0.56 and a beta of 2.34. The company’s 50-day simple moving average is $0.68 and its 200-day simple moving average is $1.08. Fractyl Health, Inc. has a 52 week low of $0.38 and a 52 week high of $2.45.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.23. As a group, equities research analysts forecast that Fractyl Health, Inc. will post -0.6 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a research report on Tuesday, May 12th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research report on Thursday, March 26th. Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, June 4th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $5.40.

Institutional Trading of Fractyl Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. FNY Investment Advisers LLC purchased a new stake in shares of Fractyl Health during the 3rd quarter valued at $31,000. Jane Street Group LLC purchased a new position in Fractyl Health in the 2nd quarter worth $31,000. Accredited Investors Inc. purchased a new position in Fractyl Health in the 1st quarter worth $46,000. Scientech Research LLC purchased a new position in Fractyl Health in the 3rd quarter worth $49,000. Finally, Prelude Capital Management LLC purchased a new position in Fractyl Health in the 3rd quarter worth $55,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.